Dr. William Hobbs believes the large unmet need among millions of sickle cell disease patients worldwide makes developing treatments a compelling business opportunity, provided the approach is based on solid biology.

Diseases with a significant unmet need like sickle cell disease require a strategy of serial innovation.

The pharmaceutical industry has largely ignored sickle cell disease for a long time.